Literature DB >> 22445570

Genetic susceptibility to experimental autoimmune glomerulonephritis in the Wistar Kyoto rat.

John Reynolds1, Paul R Cook, Jacques Behmoaras, Jennifer Smith, Gurjeet Bhangal, Susan Tadros, Jonathan Tee, Alan D Salama, David J Evans, Timothy J Aitman, H Terence Cook, Charles D Pusey.   

Abstract

In experimental autoimmune glomerulonephritis (EAG), a model of Goodpasture's disease, Wistar Kyoto (WKY) rats immunized with collagenase-solubilized glomerular basement membrane (GBM) or the recombinant NC1 domain of the α3 chain of type IV collagen [α3(IV)NC1] develop anti-GBM antibodies and focal necrotizing glomerulonephritis with crescent formation. However, Lewis (LEW) rats, which share the same major histocompatibility complex (MHC) haplotype, are resistant to EAG development. A genome-wide linkage analysis of backcrossed animals with EAG revealed a major quantitative trait locus (QTL) on rat chromosome 13 (LOD = 3.9) linked to the percentage of glomerular crescents. To investigate the role of this QTL in EAG induction, reciprocal congenic rats were generated (LEW.WCrgn1 congenic and WKY.LCrgn1 congenic), immunized with recombinant rat α3(IV)NC1, and assessed for EAG development. WKY.LCrgn1 rats showed a marked reduction in albuminuria, severity of crescentic nephritis, and number of glomerular macrophages compared with WKY controls. No reduction in antibody levels was observed. However, LEW.WCrgn1 rats were resistant to EAG development, as were LEW controls. Macrophage activation in vitro was assessed in parental and congenic rat bone marrow-derived macrophages (BMDMs). WKY.LCrgn1 BMDMs showed a significant reduction in Fc receptor-mediated oxidative burst, phagocytosis of opsonised polystyrene beads, and LPS-induced levels of MCP-1 secretion and iNOS mRNA expression compared with WKY rats. These results confirm the importance of Crgn1 on chromosome 13 in EAG susceptibility, mediated partly through differences in Fc receptor-mediated macrophage activation.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445570      PMCID: PMC3532591          DOI: 10.1016/j.ajpath.2012.01.029

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

Review 1.  The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity.

Authors:  R G Phelps; A J Rees
Journal:  Kidney Int       Date:  1999-11       Impact factor: 10.612

2.  The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease.

Authors:  John Reynolds; Jill Moss; Mark A Duda; Jennifer Smith; Ayman M Karkar; Vamshi Macherla; Ian Shore; David J Evans; David F Woodrow; Charles D Pusey
Journal:  J Pathol       Date:  2003-05       Impact factor: 7.996

3.  Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis.

Authors:  Vadim Pedchenko; Olga Bondar; Agnes B Fogo; Roberto Vanacore; Paul Voziyan; A Richard Kitching; Jörgen Wieslander; Clifford Kashtan; Dorin-Bogdan Borza; Eric G Neilson; Curtis B Wilson; Billy G Hudson
Journal:  N Engl J Med       Date:  2010-07-22       Impact factor: 91.245

4.  Nasal administration of recombinant rat alpha3(IV)NC1 prevents the development of experimental autoimmune glomerulonephritis in the WKY rat.

Authors:  John Reynolds; Evangelia I Prodromidi; Jason K Juggapah; Danielle S Abbott; Kathryn A Holthaus; Raghu Kalluri; Charles D Pusey
Journal:  J Am Soc Nephrol       Date:  2005-04-06       Impact factor: 10.121

5.  Experimental autoimmune glomerulonephritis (EAG) induced by homologous and heterologous glomerular basement membrane in two substrains of Wistar-Kyoto rat.

Authors:  J Reynolds; K Mavromatidis; S J Cashman; D J Evans; C D Pusey
Journal:  Nephrol Dial Transplant       Date:  1998-01       Impact factor: 5.992

6.  Strain susceptibility to active induction and passive transfer of experimental autoimmune glomerulonephritis in the rat.

Authors:  John Reynolds; Amina Albouainain; Mark Anthony Duda; David John Evans; Charles Dickson Pusey
Journal:  Nephrol Dial Transplant       Date:  2006-09-23       Impact factor: 5.992

7.  In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1.

Authors:  Alan D Salama; Afzal N Chaudhry; James J Ryan; Efram Eren; Jeremy B Levy; Charles D Pusey; Liz Lightstone; Robert I Lechler
Journal:  J Am Soc Nephrol       Date:  2001-09       Impact factor: 10.121

8.  Proliferative autoimmune glomerulonephritis in rats: a model for autoimmune glomerulonephritis in humans.

Authors:  W K Bolton; W J May; B C Sturgill
Journal:  Kidney Int       Date:  1993-08       Impact factor: 10.612

9.  Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease.

Authors:  Alan D Salama; Afzal N Chaudhry; Kathryn A Holthaus; Karen Mosley; Raghu Kalluri; Mohamed H Sayegh; Robert I Lechler; Charles D Pusey; Liz Lightstone
Journal:  Kidney Int       Date:  2003-11       Impact factor: 10.612

10.  Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility.

Authors:  Jacques Behmoaras; Gurjeet Bhangal; Jennifer Smith; Kylie McDonald; Brenda Mutch; Ping Chin Lai; Jan Domin; Laurence Game; Alan Salama; Brian M Foxwell; Charles D Pusey; H Terence Cook; Timothy J Aitman
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

View more
  8 in total

1.  Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'.

Authors:  John Reynolds; Gloria A Preston; Barrak M Pressler; Peter Hewins; Michael Brown; Aleeza Roth; Elizabeth Alderman; Donna Bunch; J Charles Jennette; H Terence Cook; Ronald J Falk; Charles D Pusey
Journal:  J Autoimmun       Date:  2015-04-02       Impact factor: 7.094

2.  Genetically determined severity of anti-myeloperoxidase glomerulonephritis.

Authors:  Hong Xiao; Dominic Ciavatta; David L Aylor; Peiqi Hu; Fernando Pardo-Manuel de Villena; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2013-02-04       Impact factor: 4.307

3.  Differentiating Glomerular Inflammation from Fibrosis in a Bone Marrow Chimera for Rat Anti-Glomerular Basement Membrane Glomerulonephritis.

Authors:  Cindy Zhou; Kristie Lou; Kiana Tatum; Jeremiah Funk; Jean Wu; Todd Bartkowiak; David Kagan; Yahuan Lou
Journal:  Am J Nephrol       Date:  2015       Impact factor: 3.754

4.  The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN.

Authors:  Joshua D Ooi; Janet Chang; Kim M O'Sullivan; Vadim Pedchenko; Billy G Hudson; Arthur A Vandenbark; Lars Fugger; Stephen R Holdsworth; A Richard Kitching
Journal:  J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 10.121

5.  Identification of Ceruloplasmin as a Gene that Affects Susceptibility to Glomerulonephritis Through Macrophage Function.

Authors:  Tai-Di Chen; Maxime Rotival; Ling-Yin Chiu; Marta Bagnati; Jeong-Hun Ko; Prashant K Srivastava; Enrico Petretto; Charles D Pusey; Ping-Chin Lai; Timothy J Aitman; H Terence Cook; Jacques Behmoaras
Journal:  Genetics       Date:  2017-04-26       Impact factor: 4.562

6.  An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.

Authors:  Yingjie Han; Frank Y Ma; Julie Di Paolo; David J Nikolic-Paterson
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

7.  Experimental crescentic glomerulonephritis: a new bicongenic rat model.

Authors:  Zelpha D'Souza; Stephen P McAdoo; Jennifer Smith; Charles D Pusey; H Terence Cook; Jacques Behmoaras; Timothy J Aitman
Journal:  Dis Model Mech       Date:  2013-08-15       Impact factor: 5.758

8.  ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis.

Authors:  Liv A Amos; Frank Y Ma; Greg H Tesch; John T Liles; David G Breckenridge; David J Nikolic-Paterson; Yingjie Han
Journal:  J Cell Mol Med       Date:  2018-07-11       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.